Clinical Study of DA-002 and DA-005 As a Treatment for Hair Loss

ConditionsAndrogenetic Alopecia Female Pattern Baldness Male Pattern Baldness

Trial statusNot yet recruiting

Trial phasePhase 3

Trial typeInterventional

Biological sexAll

Age18+

SponsorApplied Biology, Inc.

About this trial

The primary objective of the study is to assess the safety and efficacy of DA-005 and DA-002 as a treatment for hair loss (androgenetic alopecia).

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age 18 or older

Diagnosed with androgenetic alopecia

Willing and able to apply the treatment as directed, comply with study

Otherwise healthy

Disqualifiers

A medical history that may interfere with study objectives

Women who are pregnant, lactating, or planning to become pregnant during the study period

Subjects who have experienced a clinically important medical event within 90 days of the visit (e.g., stroke, myocardial infarction, etc)

Subjects who have known allergies to any excipient in DA-002 or DA-005

Trial design

Design model

Parallel

Treatments tested in this trial

DA-005
Dietary supplement
Oral Botanical Supplement HIF-1a inhibitor
Topical minoxidil 5%
Drug
Topical minoxidil 5%
DA-002
Drug
Topical Alpha 1 Agonist (GRAS)
Placebo Oral Tablet
Dietary supplement
Placebo Oral Tablet
Placebo Topical Solution
Other intervention
Placebo Topical Solution

Treatment groups

516 Participants

are divided into 3 treatment groups

Group A: DA-005Experimental treatment 2 interventions

Group B: Topical Minoxidil 5%Active comparator 2 interventions

Group C: DA-002Experimental treatment 2 interventions

Trial outcomes

Primary outcomes

Target Area Hair Counts

Time frame

Week [0,12]

Target Area Hair Counts

Time frame

Week [0,24]

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Applied Biology, Inc.

Lead sponsor

Follea International Limited

Collaborator

Daniel Alain, Inc.